Do NOACs Result in Any Benefit in TAVR?

Courtesy of Dr. Carlos Fava.

The need for anticoagulation after transcatheter aortic valve replacement (TAVR) is over 15% according to different reports and, so far, no one has analyzed in depth whether new oral anticoagulant agents (non-vitamin K oral anticoagulants [NOACs]) result in superior benefit compared with classic vitamin K antagonists (VKAs).

This study analyzed 962 patients. Among them, 326 received NOACs (33.9%) and 636 received VKAs (66.1%).

The primary endpoint at 12 months was a composite of all-cause mortality, acute myocardial infarction, and stroke.

Groups were similar: the mean age was 81 years, 52% of patients were women, the Society of Thoracic Surgeons (STS) score was 4.5%, and the CHA2DS2 VASC Score ≥2, 95.2%. Balloon-expandable valves were the most used valves.


Read also: Must Post MI Patients Use B Blockers for Life?


At 30 days, there were no differences in mortality, major bleeding, or life-threatening bleeding, but NOAC patients had higher rates of non-disabling stroke compared with VKA patients (1.2% vs. 0%; p < 0.001).

At 1 year, the primary endpoint was higher for NOAC patients (20.9% vs. 14.4%; hazard ratio [HR] 1.47; 95% confidence interval [CI]: 1.06 to 2.04; p 0 = 0.018); there were no differences as regards mortality, acute myocardial infarction, or bleeding. The rates of non-disabling stroke were higher for NOAC patients (1.6% vs. 0.3%; HR: 5.00; 95% CI: 0.97 to 25.81; p = 0.054).

Conclusion

Chronic use of NOACs and VKAs among patients in need of oral anticoagulation after TAVR resulted in comparable bleeding risk at 1 year. NOACs resulted in a higher ischemic event rate, something that should be evaluated in large randomized trials.

Courtesy of Dr. Carlos Fava.

Original Title: Oral Anticoagulant Type and Outcomes After Transcatheter Aortic Valve Replacement.

Reference: David Jochheim, et al. JACC cardiovasc Interven. Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...